Daniel Lenihan, MD, FACC, FESC, FIC-OS

About Daniel Lenihan, MD, FACC, FESC, FIC-OS

Daniel Lenihan, MD, FACC, FESC, FIC-OS has been active in cardio-oncology and heart failure for over 25 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor responses and novel cardiac biomarkers, as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer. He has previously held positions at MD Anderson Cancer Center in Houston, Vanderbilt University in Nashville, and Washington University in St Louis. He is currently the Director of Cardio-Oncology and Heart Failure at St Francis Healthcare, Cape Girardeau, MO.
Dr. Lenihan is at the forefront of concerted efforts to foster collaboration among a host of colleagues both regionally, nationally, and throughout the world. He is the Founder and Immediate Past President of the International Cardio-Oncology Society (IC-OS), a professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy. His current research projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis. He is the PI of the PROTECT study looking at cardiac safety in patients undergoing proteasome inhibitor treatment for relapsed multiple myeloma that was published in the Journal of Clinical Oncology (JCO) in 2019.

Education & Training

Residency

Doctoral Degree

Bachelors Degree